Day 2 - Exosomes EuropeThursday, 5 November 2026

• Evaluating legacy viral purification technologies versus next-gen chromatography for EVs
• Solving isolation challenges that prevent exosome therapeutics from advancing to clinical stages.
• Mitigating downstream bottlenecks to ensure high-purity yield in large-scale production
• Maintaining structural stability and biological potency during intensive purification cycles

• Strategies to remove co-purified viruses and cell-derived proteins.
• Validating GMP-compliant protocols for naturally derived sources
• Purity challenges for EVs isolated from living cell sources.
• Raw materials and feed analysis for improved clearance

Leveraging its proprietary platform of EV production by turbulence, EVerZom is advancing its lead therapeutic candidate, EVerGel, a thermoresponsive hydrogel loaded with MSC-derived exosomes designed for localized regenerative therapy. Upon injection, the formulation undergoes a sol–gel transition at physiological temperature, enabling sustained delivery of bioactive EV-enriched secretome directly at the lesion site. Preclinical studies in multiple animal models have demonstrated enhanced tissue repair, accelerated wound healing, and immunomodulatory effects. EVerGel™ is currently progressing toward clinical evaluation for the treatment of complex gastrointestinal lesions, including perianal fistulas associated with Crohn’s disease.

• Moving beyond isolated exosomes to utilise the complete secretomes.
• Clinical data for rare diseases.
• Utilising exosomes as adjuncts to allow tolerance for "dangerous" therapies.

• Predicting the "mRNA moment" for exosome-based vaccine and therapy delivery
• The evolution of cell-free therapeutics as a solution to scalability hurdles
• Long-term vision for standardized, high-volume exosome manufacturing hubs
• Final assessment of manufacturing breakthroughs needed in the next 5-8 years.